Search Browse Earnings

Inhibikase Therapeutics, Inc.

Nasdaq:IKT

Biological Products, (No Diagnostic Substances)·WILMINGTON, DE

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$260,501

+111.0% YoY

FY 2024

Adj. EBITDA

-$19.9M

-7643.9% margin

FY 2024

Net Income

-$19.0M

-7304.7% margin

FY 2024

EPS (Diluted)

-$3.16

FY 2024

Stock Price

$1.96

+3.4%

2026-03-10

52W Range

$1.33 – $2.58

P/E Ratio

-0.6x

Market Cap

$147.0M

Cash

$9.2M

FY 2024

Total Debt

$424,318

FY 2023

Net Cash

$8.8M

FY 2023

Enterprise Value

$138.2M

Debt / EBITDA

0.4x

FY 2024

EV / EBITDA

-6.9x

Employees

—